Article Sidebar

pdf
Date Published: 05/05/2024
Abstract Views: 147
Views pdf: 106
DOI: https://doi.org/10.51298/vmj.v538i1.9333
Issue
Vol. 538 No. 1 (2024)
Section
Các bài báo
How to Cite
Nguyễn, T. H., Đặng, T. S., & Nguyễn, H. L. (2024). EFFECTIVENESS AND SAFETY OF DAPAGLIFLOZIN VERSUS EMPAGLIFLOZIN IN TREATMENT HfrEF. Vietnam Medical Journal, 538(1). https://doi.org/10.51298/vmj.v538i1.9333

EFFECTIVENESS AND SAFETY OF DAPAGLIFLOZIN VERSUS EMPAGLIFLOZIN IN TREATMENT HfrEF

Thu Hằng Nguyễn, Thị Soa Đặng, Hữu Long Nguyễn

Main Article Content

Abstract

Empagliflozin and dapagliflozin are SGLT2i drugs used in the treatment of heart failure, demonstrating benefits in reducing mortality and admission rates compared to placebo in clinical trials. A cross-sectional descriptive study was conducted on 90 patients divided into 3 groups: control group, group using dapagliflozin 10mg and group using empagliflozin 10mg to evaluate the effectiveness and safety of dapagliflozin compared with empagliflozin in treatment. chronic heart failure at Nghe An General Friendship Hospital. The two groups dapagliflozin 10mg and empagliflozin 10mg recorded lower mortality risks than the control group (p<0.05); dapagliflozin 10mg improved symptom frequency higher than the empalifozin 10mg group (p<0.05) and empalifozin 10mg improved quality of life higher than the dapalifozin10mg group (p<0.05).

Article Details

Keywords

heart failure, KCCQ-12, dapagliflozin, empaglìlozin, effectiveness, safety

References

1. AHA/ACC/HFSA (2022), “Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”, Circulation.;145:e895–e1032.
2. Bộ Y tế (2022), “Hướng dẫn chẩn đoán và điều trị suy tim cấp và mạn”, 2022.
3. Anker SD, Butler J (2021), “Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial”, Circulation, Jan 26;143(4):pp.337-349.
4. Scott D Solomon (2021), Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial, Eur J Heart Fail Jul;23(7):1217-1225.
5. D'Amario, D. et al. (2022). "Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry", Eur J Heart Fail. 24(5), tr. 871-884.
6. Peikert A, et al (2023), “Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial”, JAMA Cardiol, 2023;8(7):684–690.